Terns Pharmaceuticals Inc

CEO Amy Burroughs’ 10b‑5‑1 trades reveal a strategic mix of deep‑discount buys and high‑price sells, underscoring personal portfolio management rather than bullish sentiment at Terns Pharmaceuticals.

CEO Amy Burroughs’ recent 10b5‑1 trades reveal a calculated balance: buying low at $4.64 while selling high near $47, signaling confidence in Terns Pharmaceuticals’ long‑term prospects.

CEO Amy Burroughs buys Terns Pharmaceuticals shares at $4.64 after selling high‑price blocks, showing disciplined Rule 10b5‑1 confidence and a potential near‑term upside for investors.

Insider confidence fuels hope for Terns Pharmaceuticals as six directors exercise $0 stock options, hinting at future breakthroughs and a potential price rebound.

Insider buying surge at Terns Pharmaceuticals: CMO, CFO, CEO lock in 356k shares and options, hinting at a bullish pipeline amid high volatility.